Cost-Effectiveness of Newborn Screening for Phenylketonuria and Congenital Hypothyroidism - 05/05/23
, Lene Sörensen, Med Lic 2, 3, Rolf H. Zetterström, MD, PhD 2, 3, Martin Henriksson, PhD 1, Anna Wedell, MD, PhD 2, 3, Lars-Åke Levin, PhD 1Abstract |
Objective |
To evaluate the long-term costs and health effects of the Swedish newborn screening program for classic phenylketonuria (PKU) alone and in combination with congenital hypothyroidism compared with no screening.
Study design |
A decision-analytic model was developed to estimate and compare the long-term (80 years) costs and health effects of newborn screening for PKU and congenital hypothyroidism. Data were obtained from the literature and translated to Swedish conditions. A societal perspective was taken, including costs falling on health care providers, municipal care and services, as well as production loss due to morbidity.
Results |
Screening 100 000 newborns for PKU resulted in 73 gained quality-adjusted life-years (QALYs) compared with no screening. When adding congenital hypothyroidism, the number of gained QALYs was 232 compared with PKU alone, adding up to a total of 305 QALYs gained. Corresponding cost estimates were $80.8, $70.3, and $10.05 million USD for no screening, PKU screening, and PKU plus congenital hypothyroidism screening, respectively, indicating that screening for PKU plus congenital hypothyroidism was more effective and less costly compared with the other strategies. The majority of cost savings with PKU plus congenital hypothyroidism screening was due to reductions in productivity losses and municipal care and services costs.
Conclusion |
The Swedish newborn screening program for PKU and congenital hypothyroidism saves substantial costs for society while generating additional QALYs, emphasizing the importance of public investments in early diagnosis and treatment.
Le texte complet de cet article est disponible en PDF.Abbreviations : ICER, PKU, PSA, QALY
Plan
| Supported by grants provided by Medical Diagnostics Karolinska. The funder played no role in the design or conduct of the study; the collection, management, analysis, or interpretation of the data; the writing, review, or approval of the manuscript; or the decision to submit the manuscript for publication. The authors declare no conflicts of interest. |
Vol 256
P. 38 - mai 2023 Retour au numéro
Article précédent
- Cost-Effectiveness of a Quality Improvement Initiative for the Clinical Management of Children with Newly Diagnosed Immune Thrombocytopenia
- Alexandra Moskalewicz, Carolyn E. Beck, Patricia C. Parkin, Michaela Cada, Myla E. Moretti
- Evolution of Ultrasound-Assessed Lung Aeration and Gas Exchange in Respiratory Distress Syndrome and Transient Tachypnea of the Neonate
- Lucilla Pezza, Victor Sartorius, Barbara Loi, Giulia Regiroli, Roberta Centorrino, Lucia Lanciotti, Virgilio P. Carnielli, Daniele De Luca
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?